2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sitten"One disappointing study" can send the stock down, yes — but Circio is less binary than a classic single-asset biotech case. This is important, because circVec is not just one vaccine or one molecule. The platform is tested in several tracks: AAV, heart, eye, CNS, LNP/in vivo CAR-T and non-viral delivery. Thus, one failed attempt can severely damage the case, but not necessarily destroy the entire platform value. The risk is not entirely like an "all or nothing" case. It's also something to be aware of. For an investor with risk tolerance, high insight and the ability to withstand large fluctuations, a larger position can be a good and deliberate choice.
I think more people here should understand this! It's not about a pharmaceutical company that makes some specific medicine.
·11 t sittenCircio is, in my opinion, one of those stocks where one must be extremely aware of the risk. The potential is undoubtedly exciting, but right now one is largely buying into a biotech company's future potential – not a company with stable revenue and earnings. There is still a long way from promising research and preclinical results to clinical results, an approved product and real commercial success. One disappointing study or a delay can therefore send the stock sharply down. The capital raise has given Circio better financial ammunition, but it does not change the fundamental risk: A lot of money still needs to be spent on development, and future financing and dilution can still become relevant. What is interesting about Circio is also what makes it dangerous: If the technology succeeds, the potential can be enormous. But if it doesn't, the downside can also be brutal. So for me, Circio is a high-risk speculation – not a stock I would put a large part of my portfolio into. 🚨 High risk 📉 Large potential downside 📈 But also possibility for very large upside That is precisely the combination one should remember before pressing buy.Circio is not a pharmaceutical company. Acquisitions may come if the technology is so good that Big Pharma will secure it. There is no 'product' Circio is involved with.
·20 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?
That you choose to ask for help in a forum most likely means that you are very inexperienced. Biotech is and remains extremely high risk. Regardless of the price you might buy at, one piece of news can send the stock down 90% in a couple of hours. At the same time, one piece of news can send it the other way, of course. If the company succeeds, it means relatively little whether you paid 6,8 or 10 kroner. Circio is very volatile and it hasn't been many days since it was all the way down to 7,7, so you must tolerate the stock fluctuating without getting nervous, and realize that the risk of losing everything overnight is relatively high.
·23 t sittenPositive mention is good. Do we then believe the share price will gain momentum on Monday? Or will it be treading water😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sitten"One disappointing study" can send the stock down, yes — but Circio is less binary than a classic single-asset biotech case. This is important, because circVec is not just one vaccine or one molecule. The platform is tested in several tracks: AAV, heart, eye, CNS, LNP/in vivo CAR-T and non-viral delivery. Thus, one failed attempt can severely damage the case, but not necessarily destroy the entire platform value. The risk is not entirely like an "all or nothing" case. It's also something to be aware of. For an investor with risk tolerance, high insight and the ability to withstand large fluctuations, a larger position can be a good and deliberate choice.I think more people here should understand this! It's not about a pharmaceutical company that makes some specific medicine.
- ·11 t sittenCircio is, in my opinion, one of those stocks where one must be extremely aware of the risk. The potential is undoubtedly exciting, but right now one is largely buying into a biotech company's future potential – not a company with stable revenue and earnings. There is still a long way from promising research and preclinical results to clinical results, an approved product and real commercial success. One disappointing study or a delay can therefore send the stock sharply down. The capital raise has given Circio better financial ammunition, but it does not change the fundamental risk: A lot of money still needs to be spent on development, and future financing and dilution can still become relevant. What is interesting about Circio is also what makes it dangerous: If the technology succeeds, the potential can be enormous. But if it doesn't, the downside can also be brutal. So for me, Circio is a high-risk speculation – not a stock I would put a large part of my portfolio into. 🚨 High risk 📉 Large potential downside 📈 But also possibility for very large upside That is precisely the combination one should remember before pressing buy.Circio is not a pharmaceutical company. Acquisitions may come if the technology is so good that Big Pharma will secure it. There is no 'product' Circio is involved with.
- ·20 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?That you choose to ask for help in a forum most likely means that you are very inexperienced. Biotech is and remains extremely high risk. Regardless of the price you might buy at, one piece of news can send the stock down 90% in a couple of hours. At the same time, one piece of news can send it the other way, of course. If the company succeeds, it means relatively little whether you paid 6,8 or 10 kroner. Circio is very volatile and it hasn't been many days since it was all the way down to 7,7, so you must tolerate the stock fluctuating without getting nervous, and realize that the risk of losing everything overnight is relatively high.
- ·23 t sittenPositive mention is good. Do we then believe the share price will gain momentum on Monday? Or will it be treading water😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sitten"One disappointing study" can send the stock down, yes — but Circio is less binary than a classic single-asset biotech case. This is important, because circVec is not just one vaccine or one molecule. The platform is tested in several tracks: AAV, heart, eye, CNS, LNP/in vivo CAR-T and non-viral delivery. Thus, one failed attempt can severely damage the case, but not necessarily destroy the entire platform value. The risk is not entirely like an "all or nothing" case. It's also something to be aware of. For an investor with risk tolerance, high insight and the ability to withstand large fluctuations, a larger position can be a good and deliberate choice.I think more people here should understand this! It's not about a pharmaceutical company that makes some specific medicine.
- ·11 t sittenCircio is, in my opinion, one of those stocks where one must be extremely aware of the risk. The potential is undoubtedly exciting, but right now one is largely buying into a biotech company's future potential – not a company with stable revenue and earnings. There is still a long way from promising research and preclinical results to clinical results, an approved product and real commercial success. One disappointing study or a delay can therefore send the stock sharply down. The capital raise has given Circio better financial ammunition, but it does not change the fundamental risk: A lot of money still needs to be spent on development, and future financing and dilution can still become relevant. What is interesting about Circio is also what makes it dangerous: If the technology succeeds, the potential can be enormous. But if it doesn't, the downside can also be brutal. So for me, Circio is a high-risk speculation – not a stock I would put a large part of my portfolio into. 🚨 High risk 📉 Large potential downside 📈 But also possibility for very large upside That is precisely the combination one should remember before pressing buy.Circio is not a pharmaceutical company. Acquisitions may come if the technology is so good that Big Pharma will secure it. There is no 'product' Circio is involved with.
- ·20 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?That you choose to ask for help in a forum most likely means that you are very inexperienced. Biotech is and remains extremely high risk. Regardless of the price you might buy at, one piece of news can send the stock down 90% in a couple of hours. At the same time, one piece of news can send it the other way, of course. If the company succeeds, it means relatively little whether you paid 6,8 or 10 kroner. Circio is very volatile and it hasn't been many days since it was all the way down to 7,7, so you must tolerate the stock fluctuating without getting nervous, and realize that the risk of losing everything overnight is relatively high.
- ·23 t sittenPositive mention is good. Do we then believe the share price will gain momentum on Monday? Or will it be treading water😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt